Pan-cancer analysis of BRCA1 and BRCA2 alterations has revealed that genome-wide loss of heterozygosity (gLOH) is a possible marker for PARPi sensitivity.51 An increase in gLOH was seen across different cancer types, including PCa, that had biallelic BRCA1/2 alterations,51 and gLOH presents a possible biomarker to evaluate PAPRi sensitivity. This evidence concerns the gene BRCA2 and cancer.